Marco Bua

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.

CXXC1-dependent IRF4 activity promotes myeloma cell fitness and sustains lenalidomide resistance.

Journal: Blood

Published: February 04, 2026

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.

Journal: Nature communications

Published: April 29, 2022

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.

Journal: Nature communications

Published: October 05, 2020

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors.

Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors.

Journal: Cancer cell

Published: December 08, 2014

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.

Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors.

Journal: Cancer cell

Published: February 21, 2014

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Journal: Blood

Published: February 06, 2013

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

Journal: Blood

Published: December 17, 2011

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 10, 2011

Showing 1-8 of 8

Last Updated: 09/26/2026